Feb. 17 at 9:01 PM
$AIM
The latest prospectus and rights offering is another example of the years of mismanagement by this leadership team. This has potential to add nearly 30,000,000 new shares.
Initially this will raise less than
$12MM.
$12 MM is not sufficient for a company that will need to conduct a Phase 3. AIM and shareholders need to hope for a partner who is excited by pancreatic or ovarian cancer results.
If AIM had been better managed for the past few years, then shareholders would not need to endure more pain thanks to the incompetency of the leadership team.
